| Transaction Date | Recipient | Shares | Type | Price | Value |
|---|---|---|---|---|---|
| 10th November 2020 | Al Kraus | 8,000 | Exercise of derivative | $3.45 | $27,600.00 |
| 10th November 2020 | Al Kraus | 8,000 | Open or private sale | $8.00 | $64,000.00 |
| 18th August 2020 | Edward Raymond Jones | 4,000 | Exercise of derivative | $3.35 | $13,400.00 |
| 31st July 2020 | Kathleen P. Bloch | 10,000 | Exercise of derivative | $5.60 | $56,000.00 |
| 5th May 2020 | Phillip P. Chan | 14,100 | Exercise of derivative | $9.39 | $132,399.00 |
| 5th May 2020 | Vincent Capponi | 10,123 | Exercise of derivative | $9.26 | $93,738.98 |
| 27th April 2020 | Vincent Capponi | 10,000 | Exercise of derivative | $2.88 | $28,750.00 |
| 27th April 2020 | Vincent Capponi | 10,000 | Open or private sale | $10.00 | $100,000.00 |
| 12th April 2020 | Efthymios Deliargyris | 140,000 | Grant/award etc. | $0.00 | |
| 10th March 2020 | Vincent Capponi | 4,677 | Open or private sale | $6.00 | $28,062.00 |
Cytosorbents Corporation
Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 3/10.
CytoSorbents Corp. engages in the research and development of blood purification technology. The company was founded by Joseph Rubin on April 25, 2002 and is headquartered in Monmouth Junction, NJ.
Ticker: CTSO
Sector: Healthcare
Industry: Medical Devices
SEC Central Index Key (CIK): 1175151
Employees: 125
Exchange: NASDAQ
Auditor Opinion:
You must Login to see Language Changes
Disclosure Language changes
You must Login to see analysis
Red Flags
There were no Red Flags found
Fundamentals
Cash at Carrying Value: $35 M (0%)
Inventory, Net: $2 M (-6%)
Assets, Current: $42 M (100%)
Property, Plant and Equipment, Net: $2 M (1%)
Other Assets, Noncurrent: $4 M (18%)
Assets: $49 M (79%)
Long-term Debt, Current Maturities: $7 M (0%)
Accounts Payable, Current: $3 M (33%)
Liabilities, Current: $16 M (57%)
Long-term Debt, Excluding Current Maturities: $8 M (0%)
Liabilities: $25 M (4%)
Common Stock, Value, Issued: $37 Th (12%)
Common Stock, Shares, Issued: $37 M (12%)
Retained Earnings (Accumulated Deficit): $195 M (3%)
Accumulated Other Comprehensive Income (Loss), Net of Tax: $530 Th (0%)
Stockholders' Equity (Parent): $24 M (0%)
Liabilities and Equity: $49 M (79%)
Cost of Revenue: $3 M (-42%)
Gross Margin: $7 M (-49%)
Research and Development: $2 M (-44%)
Operating Income/Loss: $3 M (-42%)
Other Income, net: $431 Th (-20%)
Income before taxes: $3 M (-54%)
News
Meridian Bioscience: Benefiting From A Prolonged Pandemic
9th January 2021
Cytosorbents: Concentration Risk With Covid-19 Overexposure
20th November 2020
